The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.
An article from
The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.
Published June 11, 2026
Novartis last year brokered a $12 billion deal to buy genetic medicines developer Avidity Biosciences.
Permission granted by Novartis
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study - Novartis
Gilead and Merck's latest trial success and flop
Novo underwhelmed by drug it once fought Pfizer for
City Therapeutics gets $99M to gather data on three RNAi medicines
Novartis eyes Alzheimer's and Parkinson's as it looks to expand the AOC platform acquired in its $12 billion Avidity Biosciences…
Novartis raggiunto un accordo per l'acquisizione della statunitense Avidity Biosciences, specializzata nelle terapie Rna per…
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share,…
Novartis says acquisition US biotech company Avidity Biosciences will boost mid-term growth.
Novartis reports positive Phase 1/2 del-brax data in FSHD, supporting Phase 3 development of a potential disease-modifying…
Operazione tutta in contanti con un premio del 46%. Permette al colosso svizzero di compensare l’imminente scadenza di alcuni…
